Need For Blinded Payment In Randomized Trials Is Recognized In Recent Bills
Executive Summary
Recent legislation is recognizing the need to blind patients and health care providers to sources of reimbursement in clinical trials to ensure scientifically valid results
You may also be interested in...
Third-Party Payer Effect On Clinical Trials Still Difficult To Quantify
Third-party payer policies appear to have an effect on clinical trial participation, but the impact "is difficult" to quantify, according to a draft report by Duke Evidence-Based Practice Center researchers prepared for the Agency for Healthcare Research and Quality
Third-Party Payer Effect On Clinical Trials Still Difficult To Quantify
Third-party payer policies appear to have an effect on clinical trial participation, but the impact "is difficult" to quantify, according to a draft report by Duke Evidence-Based Practice Center researchers prepared for the Agency for Healthcare Research and Quality
Comparative Effectiveness Bill Calls For Private Group To Plan Research
While getting little exposure in the new Medicare law, comparative effectiveness research is getting full attention in a bill introduced by Sen. Max Baucus, D-Mont., that offers a comprehensive roadmap toward conducting the research and disseminating findings